Nanoparticles are emerging as promising drug delivery systems for a broad range of indications. Here, we describe a simple yet powerful method to manufacture silk nanoparticles using reverse engineered Bombyx mori silk. These silk nanoparticles can be readily loaded with a therapeutic payload and subsequently explored for drug delivery applications.
Many different classes of materials can be used to generate nanoparticles (e.g. metals and many organic and inorganic materials). However, biopolymers are emerging as attractive materials because of their known biocompatibility, biodegradability and low toxicity 8 . Many biopolymers are being explored, including albumin, alginate, chitosan and silk. Of these, silk has emerged as a promising contender for development into drug delivery systems 9 . Silks of various types are produced by a number of arthropods, including spiders (e.g. Nephila clavipes) and silkworms (e.g. Bombyx mori). Silkworm silk is used far more extensively than spider silk because the silkworm is fully domesticated and its silk thus represents a reproducible starting material. Silkworm silk is a Food and Drug Administration (FDA) approved material for human use, particularly as a suture material; it has a robust safety record in humans and is known to degrade in vivo 10 . The degradation profile of silk can be fine-tuned to range from hours (low crystalline silk) to 12 months or more (high crystalline silk). Silk degradation products are non-toxic and are metabolized in the body 10 . The silk structure imparts the ability to bind small molecular weight compounds and macromolecular protein drugs 11 , making it a good material for controlled drug release. Protein drugs (e.g. antibodies) are susceptible to denaturation, aggregation, proteolytic cleavage and clearance by the immune system. However, silk stabilizes therapeutic proteins due to the buffering capacity of its nanocrystalline regions and its ability to tailor water content at the nanoscale 11 . These unique features provide physical protection and reduce payload mobility 11 and are typically not seen with other (bio)polymers. Many anticancer drug delivery systems, for example silk-based hydrogels 12 , films [13] [14] [15] and nanoparticles 16, 17 , have now been developed to exploit these features (reviewed in 18, 19 ) Here, silk nanoparticles were characterized by determining their size and charge over an extended time frame. Doxorubicin, a clinically relevant anticancer drug, was used as a model drug for drug loading and cytotoxicity studies in triple negative human breast cancer cells treated with drug-loaded silk nanoparticles.
PROTOCOL:

Preparation of a reverse-engineered silk solution from Bombyx mori cocoons
Note: This methodology is based on protocols described elsewhere 12, 27 .
1.1) Cut 5 g of dried cocoons with scissors into 5 mm × 5 mm pieces. Remove any soiled layers. 1.9) Dialyze against 1 L of distilled water and change the water at 1, 3 and 6 hours (i.e. 3 changes on the first day) and again on the next morning and evening (i.e. 2 changes on the second day), and again on the following morning (i.e. 1 change on the third day).
1.10) Collect the silk solution from the dialysis cassette and centrifuge the solution for 20 minutes at 5 °C at 9500 x g. Recover the supernatant and repeat this centrifugation process twice more.
1.11) Determine the weight of an empty weighing boat (W1) and add 1 mL of the silk solution.
Record the weight again (W2) and then dry the sample by leaving the weighing boat at 60 ºC overnight. Next, determine the total dry weight (W3) (dried silk and weighing boat). The concentration of the silk solution (w/v) is: % = (W3-W1/W2-W1) x 100.
Preparation of silk nanoparticles from reverse-engineered silk solution
2.1) Add a 5% (w/v) silk solution dropwise to acetone while maintaining a >75% (v/v) acetone solution. For example, add 9 mL of a 5% (w/v) silk solution dropwise (10 µl/drop at a rate of 50 drops/minute) to 34 mL acetone.
2.2)
Centrifuge the precipitate at 48,000 x g for 2 hours at 4 °C.
2.3)
Aspirate the supernatant and resuspend the pellet in distilled water by first dislodging the pellet with a spatula and then adding 20 mL distilled water. Use pipet tips to remove the pellet from the spatula. After vortexing for 20 seconds followed by two sonication cycles using an ultrasonic probe at 30% amplitude for 30 seconds, top up the centrifuge tube to capacity with distilled water.
2.4)
Repeat the centrifugation and resuspension step at least twice.
2.5)
Resuspend the pellet in 6 mL distilled water, as detailed in 2.3 and store at 4 °C until use. For cell culture studies, silk nanoparticle stocks can be gamma irradiated 17 .
Determination of silk nanoparticle concentration
3.1) Centrifuge silk nanoparticles at 48,000 x g for 2 hours at 4 °C.
3.2)
Collect all nanoparticles in 3 mL of distilled water, followed by two sonication cycles at 30% amplitude for 30 seconds.
3.3)
Divide the 3 mL stock of silk nanoparticles into 2 mL and 1 mL lots and transfer into preweighed 2 mL tubes. Record the total weight of the 2 mL sample. Store the 1 mL lot at 4 °C until use; this 1 mL sample will be used to generate a calibration curve.
3.4) Snap freeze and then lyophilize the 2 mL silk nanoparticle lot in a freeze dryer overnight. After freeze-drying, reweigh the 2 mL tube and calculate the amount of silk nanoparticles (mg) that was originally present in the 2 mL sample.
3.5)
Dilute the 1 mL silk nanoparticle stock with distilled water to generate a 5-point calibration curve (0.04 -7 mg/mL). Ensure that samples do not exceed the absorbance maximum.
3.6) Determine the absorbance of each standard dilution at 600 nm. This is best done using a 96-well plate setup. Plot absorbance versus concentration (mg/mL) for the standard curve. Then use this standard curve routinely to determine the concentration of silk nanoparticles in suspensions. 
Preparation of doxorubicin-loaded silk nanoparticles
4.2.3)
Next, centrifuge the silk-doxorubicin suspension at 194,000 x g for 30 minutes. Wash the doxorubicin-loaded silk nanoparticles with distilled water and repeat this procedure twice more.
4.2.4)
Pool the supernatant and note the total volume (this sample is used to determine the encapsulation efficiency).
4.2.5)
Resuspend the doxorubicin-loaded silk nanoparticles in distilled water, protect from light and store at 4 ºC until use. 
4.3) Determination of encapsulation
4.3.5) Use equation (1) to determine encapsulation efficiency:
(1) Encapsulation efficiency (%) = amount of model drug in nanoparticles x 100 model drug initially added
5.
Characterization of silk nanoparticles 5.1) Assessment of the size and zeta potential of freshly prepared and stored silk nanoparticles.
5.1.1) Store silk nanoparticles in distilled water at 4 °C and 25 °C.
5.1.2)
Measure the size and zeta potential of the silk nanoparticles on days 0, 14 and 28 using dynamic light scattering (DLS). Set refractive indices to 1.33 for distilled water and 1.60 for protein 17 . Calculate particle sizes with the user interface software.
5.2)
Morphological assessment of silk nanoparticles by scanning electron microscopy (SEM).
5.2.1)
Place a carbon adhesive disc onto an SEM stub and subsequently attach a silicon wafer.
5.2.2)
Dilute silk nanoparticles to a concentration of 1 mg/mL. Pipette 10 µL of the sample onto a silicon wafer, freeze the sample at -80°C and lyophilize overnight using a freeze drying system as per manufacturer's instructions.
5.2.3)
Coat the sample with a gold layer up to 20 nm thick using a low vacuum sputter coater.
Note: Instrument settings vary between models. The model used here is fully automated and operates by thickness only.
5.2.4)
Image samples with a scanning electron microscope at 5 kV and a 40,000-fold magnification.
6.
In vitro cytotoxicity of control and doxorubicin-loaded silk nanoparticles 6.1) Cell viability following exposure to silk nanoparticles.
6.1.1) Culture MDA-MB-231 cells in RPMI 1640 with 10%v/v FBS. Plate cells on tissue culture treated polystyrene and incubate in a humidified 5% CO 2 atmosphere at 37 °C. Routinely subculture at 80% confluence every 2−3 days. Note: The absorbance values of untreated controls serve as a reference value for 100% cell viability.
6.2) SEM of cells exposed to silk nanoparticles. Note: Instrument settings vary between models. The model used here is fully automated and operates by thickness only.
6.2.4) Image the samples by SEM using an electron acceleration of 5 kV and 700-fold magnification.
REPRESENTATIVE RESULTS:
Data were statistically analyzed as detailed previously 17 . The Student's t-test was used for sample pairs and one-way analysis of variance (ANOVA) followed by Bonferroni's multiple comparison post hoc test for multiple samples. An asterisk denotes statistical significance as follows: *P < 0.05 and **P < 0.001. All data are presented as mean values ± standard deviation (SD) and the numbers in brackets indicate the number of independent experiments.
Regenerated silk solution was prepared and subsequently added dropwise to acetone to generate silk nanoparticles via nanoprecipitation (Figure 1 ). This method yielded uniform (polydispersity index: 0.1), spherical, silk nanoparticles (106.5 nm ± 1.1) with a negative surface charge (-49.57 mV ± 0.6) (Figure 2 and 3 ). Silk nanoparticle stability in water was assessed for up to 28 days by monitoring particles size, zeta potential and morphology (Figures 2 and 3 ). Over the 28 day storage period, at either 4 °C or 25 °C, no significant change in particle size, charge ( Figure 2 ) or morphology was observed (Figure 3 ).
Doxorubicin was used as a clinically relevant chemotherapeutic model drug for drug loading and in vitro cytotoxicity studies. Three different silk nanoparticle concentrations (10, 30 and 50 mg/mL) were used to assess the drug loading capacity of the silk nanoparticles. The doxorubicin encapsulation efficiency for 10, 30 and 50 mg/mL silk nanoparticles (i.e. 2, 6 or 10 mg of silk and 232 µg of doxorubicin) was 73±2.2, 87±1.8 and 97±0.2%, respectively ( Figure 4A ). The particle size and zeta potential of doxorubicin-loaded silk nanoparticles (10 mg) were measured and compared to 10 mg silk nanoparticle controls. The particle size did not change after drug loading ( Figure 4B ), while the zeta potential of doxorubicin-loaded silk nanoparticles was significantly reduced from -49.57±0.6 mV to -43.52±0.37 mV ( Figure 4C ).
The ability of drug-loaded silk nanoparticles to deliver doxorubicin and subsequently kill cancer cells was assessed in vitro. Human breast cancer MDA-MB-231 cells were exposed to silk nanoparticles, freely diffusible doxorubicin or doxorubicin-loaded silk nanoparticles. Cell viability was assessed after a 72 hours exposure period. The IC 50 values of freely diffusible doxorubicin and doxorubicin-loaded silk nanoparticles were 0.48 µg/mL and 0.24 µg/mL, respectively while the silk nanoparticles had an IC 50 > 5 mg/mL ( Figure 5A ). At equivalent drug doses of 0.1 µg, freely diffusible doxorubicin and doxorubicin-loaded silk nanoparticles caused significant decreases in cell viability of 83±11 and 65±11%, respectively ( Figure 5B ). However, freely diffusible doxorubicin showed a substantial greater cytotoxicity than doxorubicin-loaded silk nanoparticles. These quantitative measurements were corroborated by qualitative SEM imaging (Figure 5c ). Here, control cultures showed high cellular density and a predominating mesenchymal MDA-MB-231 phenotype; similar observations were made for cultures exposed to silk nanoparticles. However, cultures exposed to doxorubicin showed a markedly different cell phenotype. At the equivalent doxorubicin dose, MDA-MB-231 cells treated with freely diffusible doxorubicin and doxorubicin-loaded silk nanoparticles showed a substantial reduction in cell numbers. Furthermore, many cells had a very broad and spread out morphology. Cultures exposed to doxorubicin-loaded silk nanoparticles showed evidence of nanoparticles (and their aggregates) associated with the plasma membrane ( Figure 5C ). 
DISCUSSION:
Various methods are available to produce silk nanoparticles, including polyvinyl alcohol blending 20 , spray drying 21 , salting out 22 , capillary microdot printing 23 , supercritical CO 2 precipitation 24 and nanoprecipitation 16, 25 (reviewed in 26 ) However, nanoprecipitation, due to its overall simplicity, is the most popular technique for generating silk nanoparticles. Therefore, the purpose of this study was to apply nanoprecipitation to reverse-engineered silk to manufacture silk-based nanoparticles that can be used for a range of applications, including lysosomotropic anticancer drug delivery.
Over the past decade, nanoprecipitation has become one of the most common procedures for the manufacture of protein-based nanoparticles 29 . Our research group 16, 17 and others 25, 26, 30, 31 have successfully applied this technology to silk; here, we present a simple but robust stepwise protocol for the generation of silk nanoparticles. Acetone nanoprecipitation yields spherical silk particles that are homogeneous in size and fall typically in the nanometer size range. Acetone has emerged as the preferred continuous phase over solvents such as methanol, ethanol, isopropanol and butanol 16, 25 . Acetone yields nanoparticles that have a reduced level of hydration when compared to the metastable 100-200 nm sized spherical micellar structures present in native and regenerated silk solutions 32 . However, there is scope to explore solvent mixtures and variations in degumming time in order to generate silk (nano)particles with potentially different properties to those described here. The protocol described here utilizes acetone as the continuous phase, which permits the manufacture of uniform spherical nano-sized silk particles (106.5±1.1 nm) that carry a negative surface charge (-49.57±0.6 mV) and that have a tight packing of the hydrophobic, crystalline silk chains 16, 17 . Overall, the described procedure requires little hands-on time and yields silk nanoparticles from a reverse-engineered aqueous silk solution (Figure 1) . Some of the key features of this procedure include the use of 60 minutes degummed silk, the appropriate drop size (approximately 10 µl/drop) and a maximum dropping rate of 50 drops/minute. Adherence to these key features results in a typical yield of 14%. These nanoparticles are robust and we provide evidence that they are stable and do not change their physical characteristics over a 28-day storage period. However, a potential caveat of the described method is the absence to generate particles over a broad size range (i.e. generating particles from the nanometer to micrometer scale while maintaining a narrow polydispersity index).
Controlling particle size, charge and shape is important for drug delivery, particularly when targeting solid tumors 33 . Particles in the 100 nm size range are emerging as ideal candidates for tumor targeting. Therefore, 100 nm sized silk nanoparticles are potential contenders as anticancer drug delivery systems for solid tumor treatments. Silk nanoparticles have a negative surface charge, which renders them easily loaded with positively charged drugs through exploitation of the electrostatic interaction 16 . However, besides charge, additional drug characteristics (e.g. logD) are also known to affect drug loading and release 34 . In the present study, doxorubicin, a weakly basic anticancer drug, was selected as a model drug candidate. The drug loading study ( Figure 4) showed that increasing the silk nanoparticle concentration led to increased doxorubicin encapsulation efficiency; 10 mg of silk nanoparticles can encapsulate 232 µg of doxorubicin. Drug loading of the silk nanoparticles, in turn, resulted in silk nanoparticles with a significantly reduced surface charge, which was direct experimental evidence confirming that the doxorubicin-silk charge interaction is important for this particular drug carrier combination.
We have previously provided evidence that silk nanoparticles can serve as a lysosomotropic drug delivery system 16, 17 . Here, we show a test using doxorubicin-loaded silk nanoparticles to treat the human breast cancer MDA-MB-231 cell line. These cells are derived from a highly invasive triple negative breast cancer (ER -/PR -/HER2 -) that is difficult to treat in the clinic 35 . Therefore, designing a drug delivery system tailored to this patient population is expected to yield tremendous benefits. In the absence of drug loading, silk nanoparticles did not affect cell viability (IC 50 values > 5 mg/mL) (Figure 5a, c) . However, at equivalent doses, significantly greater cytotoxicity was observed with freely diffusible doxorubicin than with doxorubicinloaded silk nanoparticles (Figure 5b ). The differences between the in vitro cellular pharmacokinetics of freely diffusible and particle bound drug explain this observation. The freely diffusible drug can rapidly cross the plasma membrane via diffusion, whereas uptake of the drug-loaded nanoparticles relies on endocytosis. Nonetheless, endocytic uptake of nanoparticles can enhance drug retention and overcome drug resistance mechanisms 3 . However, the true benefit of nanoparticle-mediated anticancer drug delivery is that it exploits the EPR effect to facilitate passive tumor targeting and to improve pharmacokinetics. Therefore, the use of a nanoparticle-based drug delivery approach can only be fully assessed in vivo. In vitro studies have limitations (i.e. the absence of the EPR effect) that preclude the full characterization of these types of drug delivery systems 7 .
In summary, the described methodology allows the easy manufacture of spherical silk nanoparticles of consistent size and surface charge. These silk nanoparticles can be used for a broad range of applications (e.g., cosmetics, templates for nano patterning, theranostics, lubricants, control particles for nanotoxicity studies), including their use as anticancer drug delivery platforms.
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